CPC C07D 487/04 (2013.01) [A61K 31/519 (2013.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01); A61P 37/06 (2018.01); C07D 519/00 (2013.01)] | 27 Claims |
1. A method of treating a disease or disorder associated with overexpression of PI3Kγ kinase, wherein the disease or disorder is selected from the group consisting of tumors, sarcomas, lymphomas, leukemias, lung cancer, melanoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, colon cancer, endometrial cancer, bladder cancer, skin cancer, cancer of the uterus, renal cancer, gastric cancer, myeloma, rheumatoid arthritis, multiple sclerosis, asthma, allergy, pancreatitis, psoriasis, anaphylaxis, glomerulonephritis, inflammatory bowel disease, thrombosis, meningitis, encephalitis, diabetic retinopathy, benign prostatic hypertrophy, myasthenia gravis, Sjögren's syndrome, osteoarthritis, restenosis, atherosclerosis, autoimmune hemolytic anemia, systemic lupus erythematosus, lupus nephritis, pemphigus, and inflammation, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:
2-amino-N-(1-[8-chloro-5-(2-methyl-1,1-dioxidothiomorpholin-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
2-amino-N-{1-[8-chloro-1-cyano-5-(1,1-dioxidothiomorpholin-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl}pyrazolo[1,5-a]pyrimidine-3-carboxamide;
2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1,5-a]pyridin-6-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; and
2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1,5-a]pyridin-6-yl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
or a pharmaceutically acceptable salt thereof.
|